Management Team

Mr. Portnoy has served as Chairman of the Board and Co-Chief Executive Officer of the Company since August 2011.

Since 2002, Mr. Portnoy has served as Chairman of the Board of Directors of Partner Community, Inc., which provides B2B integrations between telecommunication service providers, such as Verizon Communications Inc., and their largest enterprise customers.

Mr. Portnoy’s venture capital company lead early-stage investment rounds in Waves Audio Ltd, the world’s leading developer of audio plugins and signal processors for the professional and consumer electronics audio markets with customers that include DELL, ASUS, JVC, NEC, Denon, and Oppo. Heard on hit records, major motion pictures, and popular video games worldwide, Waves’ cutting-edge software and hardware processors are used in every aspect of audio production, from tracking to mixing to mastering, broadcast, live sound, and more.

Mr. Portnoy has been an advocate of blockchain technology and cryptocurrencies, having first purchased bitcoin in early 2012.

Mr. Portnoy graduated Magna Cum Laude in 1984 from The Wharton School of Finance at the University of Pennsylvania.

Mr. Portnoy has served as a Director and Co-Chief Executive Officer since August 2011. During this time, he has helped lead Cryo-Cell to establish a national sales force in 2012, adopt Prepacyte-CB, the most advanced cord blood processing system, in 2014 and acquire the exclusive worldwide rights to it in 2016 and purchase Cord:Use Cord Blood Bank, thereby entering the public cord blood banking industry in 2018.

Additionally, since 2002 and 2007, Mr. Portnoy has served on the boards of directors of Partner-Community, Inc. and uTIPu Inc., a private Internet-based business, respectively.

Mr. Portnoy has been engaged in managing his personal investments since April 1997. From January 1995 to April 1997, Mr. Portnoy was employed at Strome, Susskind Investments as its Chief Fixed Income Trader.

From March 1986 until November 1991, Mr. Portnoy was employed at Donaldson, Lufkin & Jenrette Securities Corp. as a Fixed Income Arbitrage Trader, with a trading portfolio ranging in size from $1 billion to $7 billion.

Mr. Portnoy graduated Phi Beta Kappa from the University of North Carolina at Chapel Hill with a degree in Economics in December 1985.

Dr. Kurtzberg is a pioneer in the cord blood field, performing the first unrelated cord blood stem cell transplant, in 1993.

She is an internationally renowned expert in pediatric hematology–oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and the novel application of cord blood in the emerging fields of cellular therapy and regenerative medicine.

Dr. Kurtzberg was awarded a lifetime achievement award from the PBMTC in 2012. She is the President of the Cord Blood Association. She previously served on the board of the Foundation for the Accreditation of Cellular Therapies and currently co-chairs their cord blood banking standards committee. She co-chairs the National Marrow Donor Program’s Cord Blood Advisory Group and is a past member of the Advisory Council for Blood Stem Cell Transplantation reporting to the Director of Health and Human Services. She is the Director of the Marcus Center for Cellular Cures at the Duke University School of Medicine.

She served as an advisor on the Oncologic Drugs Advisory Committee (ODAC) meeting held for Mesoblast, Inc. in 2020.

Mr. Mikulinsky has served as Cryo-Cell’s Chief Information Officer since March 2012.

Mr. Mikulinsky is a software technologist and serial entrepreneur.  He has been a founding member of several software enterprises and most recently served as Chief Technology Officer of Partner-Community, Inc and Chief Technology Officer at uTIPu Inc. from 2007 to 2009. 

Mr. Mikulinsky served as the Director of Enterprise Architecture at WebLayers, Inc. where he defined enterprise architecture best practices for companies like AT&T, Defense Information Systems Agency (DISA), as well as for many major banking institutions.

He contributed to the development of International systems interoperability standards at OASIS-OPEN.ORG and WS-I.ORG.

Prior to starting his professional career as a software engineer in the United States, Mr. Mikulinsky studied radio electronics at the Bauman Moscow State Technical University (BMSTU), Russia.

Ms. Taymans has served as the Company’s Chief Financial Officer since 1998.

Prior to joining the Company, she served for three years as Controller for a telecommunications company.

Ms. Taymans has worked as an accountant in both the public and private sectors for over 30 years.

Ms. Taymans graduated from the University of Maryland in 1991 with a BS in Accounting.

Mr. Schuesler is responsible for the state-of-the-art laboratory, process improvements and research at Cryo-Cell.  He also oversees PrepaCyte-CB, a 510K product which Cryo-Cell manufactures for internal use and for a select group of cord blood laboratories. 

Previously, Mr. Schuesler has held positions in molecular, gene and cellular therapies. While at Cincinnati Children’s Hospital he helped establish the Translational Trials Development and Support Lab and was part of the team that brought the first gene therapy clinical trial to the hospital. In addition, he was the manager of the Cellular Therapies Division of Hoxworth Blood Center at University of Cincinnati where his lab provided cell processing and storage services to nearly half of the marrow transplant centers in Ohio and developed the first Cytotoxic T-Cell immunotherapy product offered at Cincinnati Children’s Hospital as well as supported the pancreatic islet transplant program at the University of Cincinnati.

Mr. Schuesler holds a Bachelor of Science in Biology, and a Masters of Business Administration. He also volunteers as an auditor for the AABB.

Ms. Darrow joined Cryo-Cell in 2014 to ensure compliance to the quality, regulatory and accreditation requirements for cellular therapy and medical device products.

Prior to joining Cryo-Cell, Ms. Darrow was the Director of Quality Assurance and Regulatory for cellular therapy at the Hoxworth Blood Center at the University of Cincinnati.

Ms. Darrow, began her career in quality as a Quality Assurance Compliance Associate at a growing sterile injectable pharmaceutical company, building the non-conformance systems and establishing the training program.

Prior thereto, Ms. Darrow served as a Research Assistant at the College of Cell and Neurobiology studying how molecules regulate the effect on neural stem cells. 

Ms. Darrow earned her Master of Science from the University of Cincinnati and her Bachelor of Science in Biotechnology from Rochester Institute of Technology.

Mr. Moss is responsible for the development and implementation of Cryo-Cell’s planned infusion clinic(s).

Mr. Moss comes to Cryo-Cell after a long career in both blood and cord blood banking. Most recently, he was the Director of the LifeSouth Cord Blood Bank, which is a non-profit bank that manufactures an FDA licensed cord blood drug product. Prior to that, Mr. Moss was the Vice President of CORD:USE Cord Blood Bank, which he helped create. He was responsible for the oversight of all aspects of both public and private banking operations.

Additionally, he previously served as the Director of Operations for the cord blood program of the New York Blood Center, which is the largest public cord blood bank in the world. Prior thereto, Mr. Moss managed all laboratory operations and implemented lean manufacturing production techniques at Viacord. Mr. Moss started his career at the Hoxworth Blood Center of the University of Cincinnati.

Mr. Moss is very experienced in creating and maintaining efficient, high-quality operations in heavily regulated environments. He received a BS in Industrial Engineering from Marietta College.